Prophylaxis of varicella in children with neoplastic disease: comparative results with zoster immune plasma and gamma globulin
- PMID: 46775
- DOI: 10.1002/1097-0142(197504)35:4<1027::aid-cncr2820350402>3.0.co;2-9
Prophylaxis of varicella in children with neoplastic disease: comparative results with zoster immune plasma and gamma globulin
Abstract
The incidence and severity of varicella following a close family contact were evaluated in children with neoplastic diseases who received prophylaxis either with commerical gamma globulin or with zoster immune plasma, as compared to patients who did not receive any prophylaxis. In the untreated group, all 14 patients developed varicella, complicated by 1 case of encephalitis and 2 cases of fatal pneumonia. In the group of 17 patients who received 0.6-1.2 ml/kg body weight of gamma globulin, 16 developed varicella, complicated by pneumonia in 2 cases, with 1 death. In the third group of 27 patients who received 10 ml/kg body weight of zoster immune plasma (ZIP), obtained from healthy adults convalescing from herpes zoster, there were only 8 cases of varicella, all very mild. Thus, prophylaxis with ZIP significantly reduced the incidence of clinical varicella (p less than 0.01) and attenuated the severity of its course.
Similar articles
-
Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program.BMC Infect Dis. 2021 Jan 11;21(1):46. doi: 10.1186/s12879-020-05656-6. BMC Infect Dis. 2021. PMID: 33430796 Free PMC article.
-
Prevention of varicella by zoster immune globulin.N Engl J Med. 1969 May 29;280(22):1191-4. doi: 10.1056/NEJM196905292802201. N Engl J Med. 1969. PMID: 4181206 Clinical Trial. No abstract available.
-
Symposium on infectious complications of neoplastic disease (Part II). Immunoprophylaxis of varicella-zoster infections.Am J Med. 1984 Apr;76(4):672-7. doi: 10.1016/0002-9343(84)90293-6. Am J Med. 1984. PMID: 6201068 Review.
-
Prevention or modification of varicella using zoster immune plasma.Am J Dis Child. 1977 Jun;131(6):693-6. doi: 10.1001/archpedi.1977.02120190087020. Am J Dis Child. 1977. PMID: 194476
-
Varicella zoster vaccines.Dermatol Ther. 2009 Mar-Apr;22(2):143-9. doi: 10.1111/j.1529-8019.2009.01226.x. Dermatol Ther. 2009. PMID: 19335725 Review.
Cited by
-
Clinical pharmacology: plasma protein binding of drugs.Br Med J (Clin Res Ed). 1981 Jan 17;282(6259):212-4. doi: 10.1136/bmj.282.6259.212. Br Med J (Clin Res Ed). 1981. PMID: 6779954 Free PMC article. No abstract available.
-
Nosocomial varicella. Part I: outbreak in oncology patients at a children's hospital.West J Med. 1979 Mar;130(3):196-9. West J Med. 1979. PMID: 425501 Free PMC article.
-
Nosocomial varicella. Part II: suggested guidelines for management.West J Med. 1979 Apr;130(4):300-3. West J Med. 1979. PMID: 442627 Free PMC article.
-
Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program.PLoS One. 2019 Jul 3;14(7):e0217749. doi: 10.1371/journal.pone.0217749. eCollection 2019. PLoS One. 2019. PMID: 31269033 Free PMC article. Clinical Trial.
-
Quantitation of antibodies to varicella-zoster virus by immune adherence hemagglutination.J Clin Microbiol. 1978 Jan;7(1):6-11. doi: 10.1128/jcm.7.1.6-11.1978. J Clin Microbiol. 1978. PMID: 203604 Free PMC article.